S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NYSE:IKT

Inhibikase Therapeutics Stock Forecast, Price & News

$6.53
-0.10 (-1.51 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.48
Now: $6.53
$6.66
50-Day Range N/A
52-Week Range
$6.42
Now: $6.53
$11.80
Volume57,277 shs
Average Volume129,793 shs
Market Capitalization$65.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1895th out of 1,926 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone678 392 3419
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$65.63 million
Next Earnings DateN/A
OptionableNot Optionable
$6.53
-0.10 (-1.51 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IKT News and Ratings via Email

Sign-up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inhibikase Therapeutics (NYSE:IKT) Frequently Asked Questions

What stocks does MarketBeat like better than Inhibikase Therapeutics?

Wall Street analysts have given Inhibikase Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inhibikase Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as Inhibikase Therapeutics' CEO?

6,978 employees have rated Inhibikase Therapeutics CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Inhibikase Therapeutics' employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Inhibikase Therapeutics' key competitors?

Who are Inhibikase Therapeutics' key executives?

Inhibikase Therapeutics' management team includes the following people:
  • Dr. Milton H. Werner, CEO, Pres & Director (Age 57, Pay $307.34k)
  • Mr. Joseph Frattaroli CPA, Chief Financial Officer (Age 58, Pay $300k)
  • Dr. Roger Rush, Head of Preclinical Research
  • Dr. Surendra Singh, Head of Chemistry, Manufacturing & Controls

When did Inhibikase Therapeutics IPO?

(IKT) raised $15 million in an IPO on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Inhibikase Therapeutics' stock symbol?

Inhibikase Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "IKT."

When does Inhibikase Therapeutics' quiet period expire?

Inhibikase Therapeutics' quiet period expires on Monday, February 1st. Inhibikase Therapeutics had issued 1,800,000 shares in its public offering on December 23rd. The total size of the offering was $18,000,000 based on an initial share price of $10.00. During Inhibikase Therapeutics' quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inhibikase Therapeutics' stock price today?

One share of IKT stock can currently be purchased for approximately $6.53.

How big of a company is Inhibikase Therapeutics?

Inhibikase Therapeutics has a market capitalization of $65.63 million. Inhibikase Therapeutics employs 2 workers across the globe.

What is Inhibikase Therapeutics' official website?

The official website for Inhibikase Therapeutics is www.inhibikase.com.

How can I contact Inhibikase Therapeutics?

The company can be reached via phone at 678 392 3419.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.